Wellcome Wolfson Institute For Experimental Medicine, Queen's University Belfast, Belfast, UK
Wellcome Wolfson Institute For Experimental Medicine, Queen's University Belfast, Belfast, UK.
BMJ Open. 2023 Sep 20;13(9):e075823. doi: 10.1136/bmjopen-2023-075823.
Febrile infants 90 days and younger are at risk of invasive bacterial infections (bacteraemia and meningitis) and urinary tract infections. Together this is previously termed serious bacterial infection with an incidence of approximately 10-20%. The National Institute for Health and Care Excellence guidance advocates a cautious approach with most infants requiring septic screening, parenteral broad-spectrum antibiotics and hospital admission. Internationally, variations exist in the approach to febrile infants, with European and North American guidance advocating a tailored approach based on clinical features and biomarker testing. None of the available international clinical decision aids (CDAs) has been validated in the UK and Irish cohorts. The aim of the Febrile Infant Diagnostic Assessment and Outcome (FIDO) Study is to prospectively validate a range of CDAs in a UK and Irish population including CDAs that use procalcitonin testing.
The FIDO Study is a prospective multicentre mixed-methods cohort study conducted in UK and Irish hospitals. All infants aged 90 days and younger presenting with fever or history of fever (≥38°C) are eligible for inclusion. Infants will receive standard emergency clinical care without delay. Clinical data and blood samples will be collected, and consent will be obtained at the earliest appropriate opportunity using research without prior consent methodology. The performance and cost-effectiveness of CDAs will be assessed. An embedded qualitative study will explore clinician and caregiver views on different approaches to care and perceptions of risk.
This study was reviewed and approved by the Office for Research Ethics Committees Northern Ireland-Health and Social Care Research Ethics Committee B, Public Benefit and Privacy Panel for Health and Social Care Scotland, and Children's Health Ireland Research and Ethics Committee Ireland. The results of this study will be presented at academic conferences and in peer-reviewed publications.
NCT05259683.
90 天及以下的发热婴儿有发生侵袭性细菌感染(菌血症和脑膜炎)和尿路感染的风险。这两种感染以前被统称为严重细菌感染,发病率约为 10-20%。英国国家卫生与保健优化研究所的指南建议采取谨慎的方法,大多数婴儿需要进行脓毒症筛查、静脉注射广谱抗生素和住院治疗。在国际上,发热婴儿的处理方法存在差异,欧洲和北美指南建议根据临床特征和生物标志物检测采取量身定制的方法。目前还没有一种可供使用的国际临床决策辅助工具(CDA)在英国和爱尔兰队列中得到验证。发热婴儿诊断评估和结局(FIDO)研究的目的是前瞻性地验证一系列 CDA 在英国和爱尔兰人群中的应用,包括使用降钙素原检测的 CDA。
FIDO 研究是一项在英国和爱尔兰医院进行的前瞻性多中心混合方法队列研究。所有 90 天及以下发热或有发热史(≥38°C)的婴儿均有资格入选。婴儿将接受标准的紧急临床护理,不会延误。将收集临床数据和血液样本,并在最早适当的机会使用无需事先同意的研究方法获得同意。将评估 CDA 的性能和成本效益。一项嵌入式定性研究将探讨临床医生和照顾者对不同护理方法的看法以及对风险的看法。
这项研究已由北爱尔兰卫生和社会保健研究伦理委员会 B、苏格兰公共利益和隐私健康和社会保健小组、爱尔兰儿童健康爱尔兰研究和伦理委员会进行了审查和批准。该研究的结果将在学术会议和同行评议的出版物中展示。
NCT05259683。